MIRACLE Trial Shows 24% CR, 37% CRc; $0.75 Unit Offering Closes Today
MBRX sits 27% above its 52-week low of $0.312 on elevated volume (23× avg).
Summary
Blinded MIRACLE Part A data reveals a 24% complete remission rate and 37% composite complete remission in 62 evaluable patients, with no cardiotoxicity — a strong efficacy signal in a tough-to-treat AML population. The venetoclax-pretreated subgroup showed similar response rates, reinforcing the drug's potential. This follows the $9.3M unit offering priced at $0.75 last week, now closing today with 12.38M shares and up to 37.13M warrants. The offering is highly dilutive but provides critical cash for the company, which had a going concern warning and needed $25M. The efficacy data could support regulatory discussions and partnership interest, but the deep discount and warrant overhang will weigh on the stock.
At the time of this announcement, MBRX was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.31 to $18.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.